Kedrion is a leading biopharmaceutical company that specializes in the development, production and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as immune system deficiencies and coagulation disorders.
With a commercial presence in 100 countries, we operate through a fully integrated business model from the collection of plasma in our own centers in the United States to fractionation and production in our manufacturing facilities located in Italy, Hungary and the United States.
First Quarter 2022 Results
2021 ANNUAL RESULTS
Annual General Meeting of Shareholders 2022
CONSOLIDATED FINANCIAL STATEMENTS Q1 2022
CONSOLIDATED FINANCIAL STATEMENTS AS AT DECEMBER 31, 2021
CONSOLIDATED FINANCIAL STATEMENTS AS AT SEPTEMBER 30, 2021
CONSOLIDATED FIRST HALF RESULTS 2021
CONSOLIDATED FINANCIAL STATEMENTS Q1 2021
CONSOLIDATED FINANCIAL STATEMENTS 2020
CONSOLIDATED FIRST HALF RESULTS 2020
CONTACT & EMAIL ALERTS
Subscribe to the service in order to receive our news